Addressing unmet needs in metastatic breast cancer (MBC)

**ER+/HER2- MBC today and tomorrow**

The last **10 years** have seen a **lack of improvement** in clinical outcomes for first-line estrogen-receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) MBC¹

**Options are needed to improve progression-free survival (PFS) with first-line therapy for ER+/HER2- MBC**

**Median survival following MBC diagnosis is currently 2–4 years²**

**Only 1 in 5 MBC patients survives to 5 years³,⁴**

**New agents and combinations have the potential to transform outcomes, improving disease control while maintaining patient quality of life¹**

---